Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desogestrel is a synthetic progestin (progestogen) used primarily as an oral contraceptive, either alone as a progestogen-only pill ("mini-pill") or in combination with ethinylestradiol as part of combined oral contraceptives. It acts mainly by inhibiting ovulation through suppression of luteinizing hormone and follicle-stimulating hormone release from the pituitary gland. Additional contraceptive effects include thickening cervical mucus to impede sperm penetration and altering the endometrial lining to reduce the likelihood of implantation. Desogestrel is a prodrug, converted in vivo to its active metabolite etonogestrel, which binds with high affinity to progesterone receptors. It has minimal androgenic and glucocorticoid activity compared to earlier-generation progestins[2][5][7]. Besides contraception, it may be used for menopausal symptoms and has been studied for other hormonal indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desogestrel.